At the 20th Congress of the European Hematology Association (EHA), Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, discusses the results of the subgroup analysis of the phase 2 multicentre, randomised, open-label MCL-002 (SPRINT) study of lenalidomide, an immunomodulator with antineoplastic and antiproliferative effects, versus investigator’s choice (chlorambucil, cytarabine, fludarabine, gemcitabine, or rituximab) in patients with relapsed/refractory mantle cell lymphoma (MCL).
Subgroup analysis of the MCL-002 (SPRINT) trial of lenalidomide in relapsed/refractory MCL
3rd July 2015
Hematology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?